Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse 04:00:44 2024-04-22 pm EDT 5-day change 1st Jan Change
26.26 USD +1.00% Intraday chart for Pfizer, Inc. +1.35% -8.79%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Pfizer: new Emblaveo antibiotic approved in the EU CF
Pfizer's Emblaveo Receives European Commission Marketing Approval MT
Sector Update: Health Care Stocks Retreating Late Afternoon MT
Sector Update: Health Care MT
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer MT
Tara Health Foundation Files an Exempt Solicitation Statement with Securities and Exchange Commission CI
News Highlights : Top Financial Services News of the Day - Monday at 11 AM ET DJ
Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... Our Logo
Novavax Shareholder Shah Capital Pushes to Add 2 Nominees to Company's Board MT
Market outlook is uncertain, but optimism prevails Our Logo
News Highlights : Top Financial Services News of the Day - Monday at 7 AM ET DJ
News Highlights : Top Financial Services News of the Day - Monday at 12 AM ET DJ
PFIZER INC : JP Morgan remains Neutral ZD
Skanska Trims Scope of Work for Biomanufacturing Facility Project in US MT
PFIZER INC : Berenberg remains Neutral ZD
Health Care Stocks Steady, Moderna Climbs -- Health Care Roundup DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading MT
Sector Update: Health Care MT
Pfizer Says Phase 3 Trial of Abrysvo for Respiratory Syncytial Virus Disease Meets Primary Endpoints MT
Pfizer's RSV Vaccine Meets Primary Endpoints in Study of Participants Under 60 Years; Seeks Expanded Access MT
Pfizer: positive results for RSV in adults CF
Pfizer's Abrysvo Hits Key Goals in Adults at Increased RSV Risk DJ
Pfizer Inc Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease CI
Pfizer RSV shot meets goals in trial of high-risk adults under age 60 RE
American Airlines, Target, Others Sue Drugmakers Over Alleged Price-Fixing MT
Chart Pfizer, Inc.
More charts
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
26.26 USD
Average target price
31.62 USD
Spread / Average Target
+20.41%
Consensus
  1. Stock Market
  2. Equities
  3. PFE Stock
  4. News Pfizer, Inc.
  5. Pfizer, BioNTech Start Clinical Study On Omicron-based Vaccine